secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001193125-26-118525
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO
--------------------------------------------------------------------------------

- Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.
- Updated MICVO monotherapy data expected mid-2026; combination data with KEYTRUDA expected 2H26.
- Appointed Thomas Civik as Interim CEO; added SVPs of Global Clinical Ops, IR/Capital Markets, and Global Program Leader.
- Cash and investments $68.3M at Dec 31, 2025; expected cash runway into Q4 2026.
- FY2025 net loss $79.6M ($1.28/diluted) vs $77.3M ($1.32) in 2024; revenue $13.9M from royalty sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526118525/0001193125-26-118525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526118525/pyxs-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-118525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer